S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
My No. 1 dividend stock for a LIFETIME of income. (Ad)
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
My No. 1 dividend stock for a LIFETIME of income. (Ad)
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
My No. 1 dividend stock for a LIFETIME of income. (Ad)
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
My No. 1 dividend stock for a LIFETIME of income. (Ad)
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
NASDAQ:ALQA

Alliqua Biomedical - ALQA Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
N/A
50-Day Range
$2.20
▼
$3.23
52-Week Range
N/A
Volume
371,516 shs
Average Volume
114,400 shs
Market Capitalization
$13.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ALQA stock logo

About Alliqua Biomedical (NASDAQ:ALQA) Stock

Alliqua BioMedical, Inc. develops, manufactures, and markets high water content, electron beam cross-linked, and aqueous polymer hydrogels or gels used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It also provides contract manufacturing services to the OEM market. The company is headquartered in Langhorne, Pennsylvania.

Receive ALQA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alliqua Biomedical and its competitors with MarketBeat's FREE daily newsletter.

ALQA Stock News Headlines

September 2, 2020 | bloomberg.com
Alliqua BioMedical Announces Changes to Its Board of Directors
August 17, 2020 | reuters.com
ADYX.PK - Adynxx Inc Key Developments | Reuters
March 30, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
May 26, 2020 | www.bloomberg.com
Alliqua BioMedical to spin off and merge its Contract Manufacturing Business with TO Pharmaceuticals LLC to Create an Independe
March 20, 2020 | www.bloomberg.com
Alliqua Biomedical Announces Expansion to Its Exclusive Licensing Agreement with Celgene Cellular Therapeutics
May 10, 2019 | finance.yahoo.com
Adynxx Announces Payment Date of Special Cash Dividend Previously Announced by Alliqua BioMedical
May 6, 2019 | finance.yahoo.com
Adynxx Completes Merger with Alliqua BioMedical, Adds Pierre Legault and Matt Ruth to Board of Directors
April 22, 2019 | seekingalpha.com
Alliqua up 28% premarket on merger with Adynxx
March 30, 2023 | Investing Daily (Ad)
A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
April 11, 2019 | seekingalpha.com
Alliqua BioMedical declares $1.05 dividend
March 18, 2019 | www.nasdaq.com
Alliqua BioMedical, Inc. Estimate Momentum
January 9, 2019 | seekingalpha.com
Alliqua files for AquaMed spinoff
January 3, 2019 | seekingalpha.com
Alliqua Biomedical provides update to shareholders; shares up 23% premarket
January 3, 2019 | finance.yahoo.com
Alliqua Biomedical CEO Provides Update to Shareholders
December 29, 2018 | globenewswire.com
New Research: Key Drivers of Growth for Zillow Group, Woodward, Navistar International, Multi-Color, Ferrellgas Partners, and Alliqua BioMedical — Factors of Influence, Major Initiatives and Sustained Production - GlobeNewswire
December 17, 2018 | www.nasdaq.com
U.S. STOCKS ON THE MOVE-Goldman Sachs, Evofem, PG&E, Proteostasis - Nasdaq
December 14, 2018 | seekingalpha.com
Alliqua Biomedical up 43% premarket on NIDA funding for brivoligide
December 14, 2018 | finance.yahoo.com
What to Watch as Healthcare Stocks Continue to Outperform the Market
December 13, 2018 | www.nasdaq.com
GLMD On Watch, ARDS On The Move, MDCO Gets New CEO - Nasdaq
See More Headlines
Receive ALQA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alliqua Biomedical and its competitors with MarketBeat's FREE daily newsletter.

ALQA Company Calendar

Last Earnings
8/09/2016
Today
3/29/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & Medical Instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALQA
CUSIP
N/A
CIK
1054274
Web
www.alliqua.com
Phone
215-702-8550
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,420,000.00
Net Margins
-230.50%
Pretax Margin
N/A
Return on Equity
-71.73%
Return on Assets
-55.23%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.28
Quick Ratio
8.17

Sales & Book Value

Annual Sales
$2.22 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.65 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
5,010,000
Free Float
N/A
Market Cap
$13.46 million
Optionable
Not Optionable
Beta
2.03

Key Executives

  • Mr. David Ian Johnson (Age 61)
    Pres, CEO, Principal Financial Officer & Director
  • Dr. Phillip D. Forman M.D. (Age 60)
    DPM, Exec. VP of Clinical Affairs
  • Mr. Joseph M. Warusz (Age 63)
    CFO, Treasurer & Sec.

Key Competitors

View All Competitors













ALQA Stock - Frequently Asked Questions

How were Alliqua Biomedical's earnings last quarter?

Alliqua Biomedical Inc (NASDAQ:ALQA) released its quarterly earnings data on Tuesday, August, 9th. The company reported $0.50 earnings per share for the quarter, beating analysts' consensus estimates of ($2.70) by $3.20. The business earned $5.50 million during the quarter, compared to analyst estimates of $5.38 million. Alliqua Biomedical had a negative net margin of 230.50% and a negative trailing twelve-month return on equity of 71.73%.

When did Alliqua Biomedical's stock split?

Shares of Alliqua Biomedical reverse split on Friday, October 6th 2017. The 1-10 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Alliqua Biomedical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alliqua Biomedical investors own include Palatin Technologies (PTN), ContraVir Pharmaceuticals (CTRV), Argos Therapeutics (ARGSQ), Consolidated Water (CWCO), Biopharmx (BPMX), Ritter Pharmaceuticals (RTTR), NVIDIA (NVDA), OPKO Health (OPK), Gilead Sciences (GILD) and Tonix Pharmaceuticals (TNXP).

What is Alliqua Biomedical's stock symbol?

Alliqua Biomedical trades on the NASDAQ under the ticker symbol "ALQA."

How much money does Alliqua Biomedical make?

Alliqua Biomedical (NASDAQ:ALQA) has a market capitalization of $0.00 and generates $2.22 million in revenue each year.

How can I contact Alliqua Biomedical?

Alliqua Biomedical's mailing address is 2150 CABOT BLVD WEST SUITE B, LANGHORNE PA, 19047. The official website for the company is www.alliqua.com. The company can be reached via phone at 215-702-8550 or via email at ir@alliqua.com.

This page (NASDAQ:ALQA) was last updated on 3/30/2023 by MarketBeat.com Staff